503A vs. 503B Compounding Pharmacies: What's the Difference?

Look closely at where compounded peptides come from and two terms keep appearing: 503A and 503B. They read like bureaucratic fine print. They are actually the line between a licensed, accountable pharmacy and an anonymous vial with nothing behind it. Here is what each one means, why there is no third category however often you see one advertised, and how to check a pharmacy's licence for yourself.

Where the names come from

503A and 503B are sections of the Federal Food, Drug, and Cosmetic Act, added by the Drug Quality and Security Act of 2013. That law split pharmacy compounding into two kinds, each with its own rules, oversight, and scale.

Neither category changes that: compounded medications are not FDA-approved, and that holds across the board. What the law establishes is who is licensed to compound, under what oversight, and at what scale.

What is a 503A compounding pharmacy?

A 503A pharmacy is closer to what most people picture when they hear "pharmacy." These are typically state-licensed compounding pharmacies that prepare medications for an individual, patient-specific order, usually tied to a provider's order for a named person rather than mass production. State boards of pharmacy regulate them, with the FDA providing federal oversight, and they operate under USP standards for compounding, sterility, and quality. Most run at a smaller scale, built to fill individualized orders one at a time.

Picture the compounding equivalent of your neighborhood pharmacy, scaled for personalized formulations: adjusting a dose, combining ingredients, or preparing something that is not commercially available, for one order at a time.

What is a 503B outsourcing facility?

A 503B facility is built for scale. It registers directly with the FDA as an outsourcing facility rather than holding only a state license, and it can compound in larger batches without a patient-specific order for each one. It works under current Good Manufacturing Practice (cGMP) standards, the same framework that governs conventional drug manufacturing, which sits a meaningful step above standard state pharmacy compounding. The FDA inspects these facilities routinely, on a schedule closer to a factory than a corner store.

503B facilities exist because some compounded products need to be made at volume, for hospitals, clinics, and providers who need a reliable, consistent supply rather than one-off orders. The tradeoff for that scale is a stricter regulatory framework.

The core differences, side by side

Oversight — 503A: State board of pharmacy, with FDA involvement · 503B: Registered and inspected directly by the FDA

Order basis — 503A: Patient-specific · 503B: Can compound without a patient-specific order

Quality standard — 503A: USP standards · 503B: cGMP (manufacturing-grade)

Scale — 503A: Smaller, individualized · 503B: Larger batch production

Inspection frequency — 503A: Varies by state · 503B: Routine FDA inspection

Neither is better in the abstract. They are built for different purposes. What matters is that both are licensed, both are regulated, and both sit a world apart from an unlicensed source with no oversight at all.

Is there such a thing as a 503C pharmacy?

No. The Drug Quality and Security Act added two sections to the Federal Food, Drug, and Cosmetic Act — 503A and 503B — and federal compounding law contains no 503C category. The term comes up often enough to be worth answering plainly. It is usually a mix-up with 501(c), the part of the tax code covering nonprofit organisations, which has nothing to do with pharmacy licensing.

The practical version: if a seller describes itself as a "503C pharmacy", that is not a category anyone can be licensed under, and it is worth asking what they actually mean.

Does the FDA's 2026 advisory vote change any of this?

Not yet, and the gap between "recommended" and "in effect" is the whole point.

In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend that several substances be added to the 503A bulk drug substances list. That committee advises the FDA; it does not make rules. Before anything changes, the FDA has to decide whether to accept the recommendation and then work through notice-and-comment rulemaking, which has historically taken a year or more. The committee is scheduled to take up further substances in February 2027.

So the categories described above are unchanged, and so is the question of what any given licensed pharmacy may compound today. If you see a seller citing that vote as evidence that something is newly permitted, the vote does not say that yet.

How do you check whether a pharmacy is licensed?

This is the practical payoff of knowing the difference, because both categories are checkable.

• A 503A pharmacy holds a state licence. State boards of pharmacy publish licence lookups, and a licensed pharmacy appears in them under its legal name.
• A 503B outsourcing facility registers with the FDA, which publishes its own list of registered outsourcing facilities.
• Either route starts with a name. A seller who will not name the pharmacy has not given you anything to check.

Why this matters when you source peptides

The peptide market spans everything from fully licensed pharmacies to anonymous sellers with no pharmacy involved. Knowing the 503A/503B distinction hands you a real question instead of a leap of faith: which licensed pharmacy is compounding this, and is it a 503A or 503B facility?

A seller who cannot answer, who cannot name a specific licensed 503A or 503B pharmacy, has no compounding pharmacy in the chain at all. That is the line between a regulated medication and an unregulated one, whatever the packaging looks like. A source that works with licensed 503A and 503B pharmacies operates inside a real structure: state and federal oversight, USP or cGMP quality standards, and a license you can check. That is the standard worth looking for.

Two related questions are worth reading alongside this one: how to buy peptides safely online, and what "research use only" on a label means. The same checkable-facts principle runs through both.

The short version

503A and 503B are not interchangeable words for "compounding pharmacy." They are two distinct, regulated categories, each with its own oversight body and quality standard, and both sit a licensed, accountable step above any source that skips a pharmacy entirely. There is no 503C. When you are weighing where a compounded peptide comes from, "is this a 503A or 503B facility, and can you name it" is one of the most useful questions you can ask.

How this applies to IronMend

IronMend is a storefront, not a pharmacy and not a medical practice. Every compounded therapy in the catalogue, sermorelin included, is prepared by a US-licensed compounding pharmacy and is available only after a licensed provider reviews the order. Prescriptions are issued at the provider's discretion, based on medical necessity, and compounded preparations are not FDA-approved. More detail on how that works sits on the sourcing and provider review page.

Regulatory framework described here follows the FDA's guidance on human drug compounding (fda.gov/drugs/human-drug-compounding) and the Drug Quality and Security Act of 2013 (21 U.S.C. §§ 353a and 353b).

Compounded medications are not FDA-approved; the FDA does not review them for safety or effectiveness before marketing. Nothing here is medical advice.